This inventor holds 1 USPTO granted patent. Top assignee: University of Washington. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Innovations of Leslie Chan in Biocompatible Polymers
Introduction
Leslie Chan is an accomplished inventor based in Seattle, WA (US). He has made significant contributions to the field of biocompatible polymers, particularly in the treatment of thrombotic and hemostatic disorders. His innovative work has the potential to enhance medical treatments and improve patient outcomes.
Latest Patents
Leslie Chan holds a patent for a "Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders." This invention involves a biocompatible polymer to which a plurality of clot-modulating peptides (CMPs) are bound. The polymer comprises repeating units of hydrophilic monomers and display monomers to which the CMPs are attached. The CMPs can include fibrin binding peptides (FBPs) that enhance clot formation by cross-linking during fibrin polymerization. The polymers can modulate clotting in various ways through the multivalent display of fibrin-binding peptides and other clot-modulating moieties. Additionally, imaging agents and therapeutic agents can be conjugated to the polymers to facilitate imaging of blood flow and thrombosis, as well as for the treatment of clotting-related disorders. Leslie Chan has 1 patent to his name.
Career Highlights
Leslie Chan is affiliated with the University of Washington, where he continues to advance his research in biocompatible materials. His work is recognized for its innovative approach to addressing complex medical challenges.
Collaborations
Leslie has collaborated with notable colleagues, including Suzie H Pun and Nathan J White. These collaborations have further enriched his research and contributed to the development of his patented technologies.
Conclusion
Leslie Chan's contributions to the field of biocompatible polymers represent a significant advancement in medical technology. His innovative patent has the potential to improve treatments for thrombotic and hemostatic disorders, showcasing the importance of research and collaboration in the medical field.